Key Takeaways
- Jabil Inc. has acquired Pharmaceutics International, Inc. (Pii) to enhance its pharmaceutical manufacturing capabilities.
- The deal strengthens Jabil’s contract development and manufacturing organization (CDMO) services, including aseptic filling, lyophilization, and oral solid dose production.
- This move supports Jabil’s growing role in drug development, clinical trials, and large-scale commercialization.
Jabil Inc. (NYSE: JBL) has completed the acquisition of Pharmaceutics International, Inc. (Pii), a specialized contract development and manufacturing organization (CDMO). The acquisition, finalized on February 3, 2025, enhances Jabil’s pharmaceutical solutions, expanding its drug development and manufacturing capabilities to better support pharmaceutical companies worldwide.
Pii brings expertise in aseptic filling, lyophilization, and oral solid dose manufacturing, complementing Jabil’s parenteral drug delivery solutions such as auto-injectors, pen injectors, and on-body pumps. This strategic move allows Jabil to provide end-to-end pharmaceutical support, from early-stage drug development to commercial production at scale.
Enhancing Drug Development and Global Supply Chains
Founded in 1994, Pii operates four Good Manufacturing Practice (GMP) facilities in Hunt Valley, Maryland, spanning over 360,000 square feet. The facilities include high-potency containment suites, aseptic injectable manufacturing, and advanced formulation labs, enabling Jabil to expand its pharmaceutical production capabilities significantly.
With this acquisition, Pii gains access to Jabil’s extensive global infrastructure, automation technologies, and supply chain efficiencies, allowing it to enhance responsiveness and innovation for pharmaceutical partners. By integrating Pii’s specialized expertise, Jabil strengthens its position in the growing CDMO market, supporting the rapid scaling of new drug therapies worldwide.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
